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ABSTRACT
Given the pressing worldwide need for measles vaccination coverage, measles vaccine
administration via inhalation is a viable option which overcomes many obstacles
currently facing vaccine distribution. Although aerosolization is well understood,
studies have focused on pharmaceuticals and very little data is available regarding
vaccines. The proposed study analyzes the relationships between various pre- and
post-aerosolization parameters in order to calculate the "aerosol fingerprint," or
combination of pre-aerosolization parameters optimized to produce the most effective
aerosol particle size distribution for measles vaccination. Relevant pre-aerosolization
parameters are identified as relative humidity, nebulizer temperature, vaccine
reconstitution, solution pH, surface tension, viscosity, air pressure, and nebulizer
geometry. Relevant post-aerosolization parameters are identified particle size
distribution, aerosolization endurance and bioavailability, and drug delivery rate.
Sensing, actuation, automation and special concerns for each variable are considered.
Thesis Supervisor: J. Kim Vandiver
Title: Professor of Mechanical and Ocean Engineering

Acknowledgements
First I would like to thank Jose-Gomez Marquez for inviting me into his research and
allowing me to define this thesis in the way I found most interesting and personally
valuable. His technical advice made this paper possible, and I'm especially grateful for
his desire to be supportive when work was the most stressful.
I would also like to thank Amit Srivastava for lending his expertise and knowledge in
vaccines, and his patience in helping me remember chemistry lessons long forgotten.
I am indebted to Professor Vandiver for his support throughout my last year at MIT,
especially in this thesis project.
I am deeply grateful to Professor Asada, my academic advisor, who supported me and
remained on my side through my less-than-smooth path through MIT.
I would also like to mention Professors Eric Hudson and Haynes Miller, for the
confidence they displayed in me early in my undergraduate career, when it was most
needed. Their gestures were so small I doubt they remembered them by the end of the
day, but I still remember clearly after more than three years.
And finally, I would like to thank my parents, family and friends, who have supported
me throughout my whole life and especially during the past four years.

Table of Contents
1. In tro d u ction............................. ............................................................. ........................ 9
1.1 Need for and Justification of Measles Vaccine Inhalation Technology........... 9
1.2 Need for Aerosol Fingerprinting................................... ......................................... 10
1.3 Overview of Proposed Experiment ........................................................................... 11
2. Pre-Aerosolization Parameters ............................................................. ........................ 12
2.1 Relative Humidity ................................................. .................................................... 12
2.2 Nebulizer Temperature............................................................................................... 14
2.3 Vaccine Reconstitution................................................................................................... 15
2.4 S olu tion p H ............................................................... .................................................... 16
2.5 Su rface T en sion ............................................................................................................... 17
2.6 V isco sity ..................................................................................... .................................. 18
2.7 A ir P ressu re ............................................................... .................................................... 19
2.8 Nebulizer Geometry ................................................................... .............................. 19
3. Post-Aerosolization Parameters....................................... ............................................. 22
3.1 Particle Size Distribution ........................................................................................ 22
3.2 Flow Rate and Drug Output................................... .................................................... 22
3.3 Aerosol Endurance and Bioavailability after Lung Deposition......................... 23
4. Data Logging and Analysis ................................................................................................. 24
5. Fu tu re W ork .......................................... ............................................................................ 24
5.1 Integration with Development of Aerovax Device................................................. 24
5.2 Expansion to Other Vaccines ....................................................... 25
6. C on clu sion ... .................................................................................................... . ..... 26
Appendix A: Summary Table of Variables .............................................................. 27
R eferen ces ................ ........ ........ ............. ........ ........................................................ ..................... 2 9
8
1. Introduction
1.1 Need for and Justification of Measles Vaccine Inhalation Technology
The World Health Organization estimated that in 2002, 1.4 million children
under five years of age died from vaccine-preventable diseases. Of this total, 510 000 of
those deaths, or 36 percent, were caused by measles'. Although measles vaccine
coverage has been improving in recent years, there were still 197 000 measles-related
deaths worldwide in 2007 (WHO Measles) 2.
Despite this progress, measles vaccine administration remains a logistical
challenge throughout the developing world. A large percentage of the world's poor live
in rural and isolated areas, making vaccine distribution (and indeed any medical
intervention) difficult or even impossible. Also, as vaccines are extremely heat-sensitive
and must be kept within a narrow temperature range to prevent the denaturing of the
essential proteins, delivery depends on the integrity of the cold chain. Given the
unreliable or even nonexistent access to electricity in most of these resource-limited
settings, the need for refrigeration is one of the most important obstacles to universal
vaccine coverage. Additionally, the use of hypodermic needles for vaccine
administration poses a large public health hazard. Needle misuse and reuse is
common, as resources are scarce and medical personnel often lack appropriate training 3.
Lack of adequate biohazardous waste facilities further poses a problem with safe
disposal of used materials.
These obstacles can be overcome by the adaptation of aerosolization technology
to the administration of vaccines. Aerosolization, or nebulization, has long been used to
administer medication directly to the lung in the treatment of respiratory illnesses such
as asthma and chronic obstructive pulmonary disease. The effective use of the
technique for the purposes of vaccination was demonstrated as early as 19604. Further,
a study done in 1984 demonstrated that measles vaccination by inhalation in fact
produced a greater antibody response when compared to traditional subcutaneous
administration by injection. This result was corroborated by further studies in 20006
and 20027. The World Health Organization has recognized the potential benefits of this
technology and is actively sponsoring research through the Measles Aerosol Project,
which seeks to facilitate the development of "aerosol vaccination devices"8.
One suitable device is Aerovax, which is currently under development at MIT.
Aerovax is an appropriate technology device designed to allow local health care
workers to administer aerosolized vaccines in extremely resource-limited settings with
very little medical training. The device is needle-free (and therefore safe and painless),
portable, and low-cost. The device's jet nebulizer can be operated on energy supplied
by a battery, human, or compressed air, making it usable even in areas where the
infrastructure necessary to operate developed-world medical devices is unreliable or
non-existent. Initial development of the device is focused on aerosolization of
commercially available injectable measles vaccine. However, more data is needed
about the optimal aerosolization of reconstituted vaccines.
1.2 Need for Aerosol Fingerprinting
Although many studies have investigated the mechanics of aerosolization (both
in general and in relation to specific drugs) and the mechanism of particle deposition in
the lung tissue, very little work has been done which is directly useful to the
development of an effective vaccine aerosolization device. Reconstituted vaccines have
different physiochemical properties (which affect droplet formation) and endurance
requirements (which relate to post-deposition efficacy) than drugs which have been
tested. Additionally, previous studies have focused on simple relationships and have
not attempted to optimize across multiple variables. Numerous parameters have been
shown to affect droplet formation (which in turn affects lung deposition), but none of
these parameters have been optimized to achieve the aerosolization with the ideal
particle size distribution for that same purpose9. An experiment identifying the "aerosol
fingerprint," defined as the parameters for optimal aerosolization, has been proposed to
further the development of the Aerovax device and ensure that the resulting technology
incorporates the relationships between pre- and post-aerosolization variables in order to
produce the most efficacious vaccine possible. This paper will focus on the
identification of the variables relevant to optimization, and an overview of known
relationships, the appropriate choice of sensor and actuator for the automated
experiment, and discussion of important considerations for each.
1.3 Overview of Proposed Experiment
A high-throughput experiment with feedback will allow aerosol fingerprint
mapping, whereby multiple variables can be controlled and measured at once. A
baseline sample of buffer (normal or phosphate buffered saline, which are typical
vaccine diluents) will be nebulized for 30 seconds, producing an aerosol cloud whose
particle size distribution will be analyzed and recorded. A computer-controlled
actuation system will then cycle through a range of input parameters, creating a full
matrix mapping all combinations of these parameters to the corresponding particle size
distribution and other output variables. A feedback loop will then focus on promising
pre-aerosolization parameter regions, narrowing down the possible parameters of the
aerosol fingerprint. This will be repeated with a measles vaccine simulant (such as an
enzyme whose activity can be measured post-aerosolization to assess if the
aerosolization process caused any protein degradation), and then with the
commercially available live attenuated measles vaccine to verify the effectiveness of the
deduced aerosol fingerprint. Plating of the aerosolized vaccine will then determine the
effect that the process has its bioavailability. Finally, an Andersen Cascade Impactor
will be used to simulate the filtering action of the human respiratory tract, verifying that
the aerosolized particles are able to penetrate to the appropriate level of the respiratory
tract and deposit live vaccine.
Important pre-aerosolization parameters are relative humidity, nebulizer
temperature, vaccine reconstitution, solution pH, surface tension, viscosity, air pressure,
and nebulizer geometry. Relevant post-aerosolization parameters are particle size
distribution (PSD), aerosolization endurance and bioavailability, and drug delivery rate.
The results of this experiment will allow development of the Aerovax device to
focus on the factors which will directly affect the successful administration of the
vaccine.
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Figure 1. Schematic of the proposed experiment
2. Pre-Aerosolization Parameters
2.1 Relative Humidity
Since the Aerovax device is being developed for use all across the world, it must
be functional in a wide variety of climates, from the deserts to the tropics. Therefore it
is imperative to study the effect that ambient relative humidity has on droplet
formation. Humidity is known to affect output particle size distribution indirectly
through its effect on nebulizer temperature0 . However, this is not an important
relationship for our purposes because we will also be measuring temperature
independently of humidity. Relative humidity is important, however, because it can
lead to post-aerosolization clumping 1.
We will measure humidity using a Honeywell HIH-4000 Series integrated circuit
humidity sensor, which operates between 0% and 100% relative humidity. This sensor
was chosen because it can operate within the temperature range of -40 C to 80' C,
which is well within the temperature range which can be expected in the testing
scenario. More importantly, however, the sensor output is an analog voltage which is
nearly linear with relative humidity. This allows the signal from the sensor to be read,
converted, and recorded by data logging software.
We will vary the humidity with a commercially available humidifier designed
for home use, the Honeywell QuietCare Cool Moisture Humidifier (HCM650). This
model was chosen because it features a digital control system which allows the user to
set and maintain exact humidity values, eliminating the need for feedback control
between the sensor and the actuator. Computer control will be accomplished by
modifying the device to send and receive signals from the data logger. The relative
humidity should be tested along the full range of 0% to 100% to represent the full array
of conditions the device will encounter.
As relative humidity will not be possible to manipulate in the field, it must be
treated separately from the other pre-aerosolization parameters. Ideally the humidity
would not affect output parameters, but in the case that it does, the variable cannot be
included in the optimization feedback loop. Instead, it should be considered as a local
variable within the context of appropriate technology design. Optimized aerosol
fingerprints can be identified at various values along the full range. With this
information, various iterations of the device could be developed to operate properly in
all climatic regions of the world.
2.2 Nebulizer Temperature
During the nebulization process, a well-documented decrease of about 10"C in
the nebulizer temperature takes placeo. Phipps, et al indicated that the falling
temperature of the nebulizer led to a reduction in the particle size distribution 12
The sensor to be used to measure temperature is a Flexible Hermetic Sealed PFA
RTD Sensor Probe, which was chosen because the experimental temperatures will fall
well within the range of the sensor (which is -60'C to 260'C) and because the probe has
a standard four wire configuration which will allow for easy integration with data
logging software. Also, the sensor simply consists of a thin, flexible wire which can be
easily inserted into the nebulizer and remain operational throughout the length of the
trials, allowing real time measurement.
The temperature will be controlled through a simple heating coil, the Amana
Dryer Element Restring Kit. This was chosen because it is a simple heating coil
designed as a replacement part for a commercial product. As a consequence, it has no
additional features or circuits, allowing us to easily control the heat output by simply
controlling the current flow through the coil. The exact relationship between applied
voltage or current and temperature must be established experimentally to allow for the
automation of the temperature control.
Because a change occurs during the process, the important factor to consider here
is the length of time it takes for the system to reach a steady state temperature, and how
that compares to the length of time necessary to dispense a single dose. This delivery
time will depend on the values of other parameters in the final aerosol fingerprint (see
Section 3.2), but should be on the range of a few minutes or less. If time to achieve a
steady state temperature is not a small portion of the total drug delivery time, patients
could receive different doses based on the order in which they were vaccinated. In this
case, further study into the relationships involved will be necessary.
For the purposes of this experiment, this time-dependent relationship can be
simplified by implementing a feedback loop between the temperature sensor and
actuator. Each trial will be designed to take place at a certain temperature, and
feedback from the sensor will adjust the output from the actuator to ensure that only
small fluctuation in the nebulizer temperature occur over the trial.
2.3 Vaccine Reconstitution
Vaccine reconstitution comprises two variables: buffer solution and solute
concentration. These two parameters will be the main factors affecting several chemical
properties which are known to affect droplet formation, namely pH, surface tension,
and viscosity. Although all five variables are closely interrelated, I will consider each
separately because in most cases variation along one parameter is still possible without
variation along all others. For example, surface tension will vary with choice of buffer
solution and solute concentration, but it can still be varied independently of the other
two. Also, even though complex interrelations exist between the variables,
understanding the basic effect that each has on nebulization will be useful.
Vaccine, the solute, is dissolved in diluent for injection. A more dilute solution
might be necessary for nebulization (compared to the injectable solution). This would
necessitate a longer exposure time to the aerosol to achieve the same does.
Solute concentration of nebulized drugs is known to increase with time, as water
evaporates from the gas-liquid surface at a rate faster than drug-saturated diluent is
nebulized 9. Concentration as a function of time can be expressed by the equation
I 10(WW+.S)
Vo -(W+S)Ft
where W and S are the output per liter of air (in mL/L) of the solution and solvent,
respectively, F is the flow rate, and Vo is the initial volume.
Since this relationship is a result of the jet nebulization technology it cannot be
altered. Therefore our trials will investigate the effect that the initial concentration has
on the output parameters. We can expect it to affect the drug delivery rate directly (see
Section 3.2), but we hope to discover if it also affects particle size distribution.
The buffers to be used are tris-buffered saline and phosphate buffered saline,
because these are commonly used in other vaccine reconstitutions 13 . The two will be
tested separately to determine if the choice of buffer solution has any effect on the
relevant output parameters. Solute concentration will be controlled by manually
varying the vaccine formulation and recording the values used.
Since concentration increases over time, precipitation of the vaccine out of
solution is a possible concern. The range of concentrations tested will be limited to
those which prevent that danger.
2.4 Solution pH
No studies have attempted to determine the possible relationships between pH
and aerosol generation, but as a wide range of pH values can be generated using buffer
solutions, it merits investigation as a possible source of aerosol improvement.
The experiment will use a Lazar Ultra-M micro pH electrode, which was chosen
because it operates on the full pH scale with a resolution greater than needed for the
experiment, and because it has a digital output which can be read by a data logger. Its
small size allows it to be fixed in the device during the trial and provide real-time
measurements.
If a significant change in pH is found to occur during the length of a single trial
(which might occur because of the varying rates of aerosolization and evaporation as
discussed in the previous section), further investigation will be necessary.
The pH will be controlled by the addition of the buffer solutions, prepared
according to commonly available buffer solutions and not to exceed the range within
which the vaccine remains viable. Automated titration is possible with a computer
controlled actuator which would release prepared solution in response to an electrical
signal. The pH should be varied along a wide range centered on the normal value
(sterile water has a pH value around five). However, drastic changes in pH might
damage the live vaccine. The actual safe range of pH values must be determined
experimentally.
2.5 Surface Tension
Surface tension has been shown to affect droplet formation. Surface tension
represents the tendency of a liquid to resist changes in surface area. Since droplet
formation represents an increase in total surface area, the energy required for
nebulization can be expressed by multiplying the surface tension by the increase in
liquid surface area 4. Therefore a higher surface tension relates to larger droplets which
are formed more slowly5 .
We will measure surface tension using the pendant drop method. Because none
of the methods available for measuring surface tension can be performed in the
nebulizer, each reconstitution will be analyzed before aerosolization and manually
recorded. The pendant drop method is more reliable than other available measurement
methods, and can be performed with a device such as the Kruss machine, which uses a
drop-fitting software package to calculate the surface tension.
Surface tension can be decreased by the addition of surface acting agents, or
surfactants. Surfactants are molecules which consist of a hydrophilic head and a
hydrophobic tail, enabling them to gather at the liquid-gas interface and reduce the
surface tension of the liquid. Possible surfactants include cetyl alcohol and lecithin,
both of which are non-toxic and are regarded as safe for human consumption. Values
along the full range (from maximum to minimum surface tension for each solution)
should be tested. The relationship between surfactant concentration and surface
tension will be determined experimentally beforehand to allow for automation.
It is important to note that a study of the use of surfactants in aerosolization
suggested a correlation of surfactant use with reduction in particle delivery to the
lung11. Although the conditions in the study were different from those in this
application (the study attempted to promote cetyl alcohol adsorption through
prolonged contact post-aerosolization, while in our scenario contact will be shorter and
occur pre-aerosolization), it is important to note that surface tension cannot be treated
as a valid parameter in the aerosol fingerprint until aerosol endurance and bioavilability
of the live attenuated vaccine after treatment with surfactant have been measured.
Before the addition of surfactants can be automated and included in the aerosol
fingerprint mapping process, surfactant-treated live vaccine must be aerosolized to
determine the effect the agents have on lung deposition and bioavailability.
2.6 Viscosity
The effect that viscosity has on nebulizer output appears to be complex and not
very well understood. Increased viscosity seems to be associated with reduced particle
size, but the relationship is stronger in the extremes of the range (jet nebulizers are
unable to aerosolize extremely viscous liquids, whereas changes in the middle range of
viscosity values lead to relatively small changes in particle size distribution). Viscosity
also appears to affect the behavior of the liquid-gas interface in the nozzle region,
resulting in decreased mass flow (and therefore increased nebulization time)4 .
However, we will not measure the viscosity directly, as the only factors which
can affect the viscosity (vaccine reconstitution and temperature) are already being
recorded. This simplifies the experiment somewhat by eliminating a variable which can
be difficult to measure without actually ignoring any relevant information.
2.7 Air Pressure
Typically the air pressure required for nebulization is between 40 and 60 pounds
per square inch (psi). This parameter has a direct effect on the output flow rate, but it is
unclear how it also affects the particle size distribution.
The air pressure can be easily controlled and measured by the use of a pressure
regulator attached to the Precision Medical EZ Neb PM7 air compressor used to operate
the nebulizer. We will test pressures within the 30-70 psi range in order to the able to
examine data outside the usual range.
2.8 Nebulizer Geometry
The effect that nebulizer geometry has on particle size distribution is not well
understood. It is widely recognized that different nebulizers produce aerosols with
different properties, but studies usually just keep track of different models, and not the
variables which differentiate them. As a preliminary step, this study will associate
different nebulizer models with their geometries in an attempt to discover possible
relationships between nebulizer geometry and aerosol output.
Aerosolization within jet nebulizers occurs in two stages. First, the high pressure
air from the compressor flows through the central tube, creating a pressure differential
between the top and bottom of the liquid reservoir. This causes the liquid to rise up the
liquid feed tube and come into contact with the flowing air just before the nozzle (see
Figure 2). Primary droplet formation occurs at this interface as the flowing gas breaks
particles free from the liquid surface. These particles are still slightly too large for
effective inhalation, so secondary droplet formation is induced by placing baffles
between the jet nozzle and the final output stream. Particles crash against these baffles
and are broken into smaller particles which are of an appropriate size for deposition in
the lungs.
jet nozzle
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Figure 2. Schematic diagram of a typical jet nebulizer
The following three dimensions might be of interest in studying the effect that
nebulizer design has on the resultant particle size distribution: the jet nozzle diameter,
the baffle surface area, and the distance between the jet nozzle and the baffle9.
Figure 3. A typical jet nebulizer and its component parts.
Unfortunately, this experimental setup is limited to currently available nebulizer
designs and whatever geometric parameters they happen to have. Ideally, these
geometric parameters could be studied directly, by using a specially designed
adjustable nebulizer. If a nebulizer with an adjustable nozzle diameter were used in
several trails, a direct correlation between nozzle size and particle size distribution
could be formulated if such a correlation existed. Likewise a more definitive
understanding of the effects of the other nebulizer dimensions could be gained,
potentially leading to a quality improvement in all nebulization. Based on current
approximate values and a desire to examine data across a wide range centered on those
values, the nozzle diameter would be varied from 2-6 mm, the baffle surface area would
be varied from 1-10 mm 2, and the nozzle-to-baffle distance would be varied from 1-5
mm.
3. Post-Aerosolization Parameters
3.1 Particle Size Distribution
The deposition of inhaled particles in the lungs has been studied extensively, and
particle sizes of about five to six microns are considered optimal for lung delivery. The
characteristic droplet measurement is the mass median aerodynamic diameter
(MMAD), which represents the droplet's effective size based on its behavior in fluid
flow. A diffraction sensor can be used to measure the particle size distribution (PSD) of
the aerosolized liquid. We will use a Malvern Spraytec Laser Diffraction instrument to
measure this distribution.
The particle size distribution is the key factor in determining the success an
aerosol will have in penetrating the respiratory system and depositing biologicals in the
lung. For this reason, the PSD will represent the primary dependent variable of the
experiment. The geometric standard deviation (GSD), which reflects the tightness of
the distribution, will also be recorded. The optimization algorithm will seek to vary the
pre-aerosolization parameters in order to create a PSD closely clustered around the
ideal value of five microns.
3.2 Flow Rate and Drug Output
The pre-aerosolization parameters don't just have an effect on the particle size
distribution, they also affect the flow and drug delivery rates. Nebulizer geometry and
air pressure will have the largest effect on these variables. While the drug delivery rate
is not related to the general effectiveness of the vaccine inhalation, it is important to
know so that the vaccine can be properly administered in the field. If we measure the
drug delivery rate and store the data, we will be able to use it later (after a final aerosol
fingerprint is chosen).
The easiest and most common method of measuring drug delivery rate is to
weigh the nebulizer before and after use to calculate the mass which was emitted over
time. This is usually expressed in units of grams per minute (g/min). Although this
method does tend to overestimate the actual rate because it fails to take into account the
changing concentration, it is useful for the purposes of comparison 6. Considering the
high throughput nature of the proposed experiment, this slightly inaccurate method can
still be utilized to compare different aerosol fingerprints to determine which are feasible
in the field. (For example, one potential aerosol fingerprint might have a much lower
drug delivery rate and therefore a much longer nebulization time, which might make it
a less appealing option despite its slightly better PSD.) However, we must keep in
mind that this calculation is an overestimate, and a better understanding of the actual
drug delivery rate of the chosen aerosol fingerprint must be developed before
implementation with human subjects.
3.3 Aerosol Endurance and Bioavailability after Lung Deposition
The vaccine's aerosol fingerprint will define the "most effective" aerosolization,
defined as the aerosol with the PSD most closely clustered around five microns. This is
the single most important factor in ensuring that delivery to the lung occurs; however,
it does not take into consideration the fact that the nebulized material is in fact
biologically live. Several of the pre-aerosolization parameters (notably pH and
temperature) could damage or kill the live attenuated vaccine, rendering it less
effective. Therefore a biological test is necessary to ensure that the aerosol optimization
did not disrupt the biological effectiveness of the vaccine.
Because measles vaccine is a controlled substance, we will avoid using it as much
as possible. Once the aerosol fingerprint has been identified, a first simulation of the
bioavailability test can be done with another agent, such as an enzyme or bovine serum
albumin (BSA). The pre- and post- aerosolization activity of the enzyme can be
compared to determine if any damage was done to the proteins during nebulization. If
this test indicates a drop in biological activity, the choice of aerosol fingerprint can be
reevaluated and the simulation run again, all without exposing any measles vaccine.
When an aerosol fingerprint which seems biologically viable has been identified,
live attenuated measles vaccine can be nebulized using those identified parameters.
The resultant aerosol will be deposited in Vero cells and plaque forming units counted.
Finally, to test both requirements (particle size and bioavailability) at once, the
aerosolized vaccine will be passed through an Andersen cascade impactor (a device
which simulates the increasingly fine filtration which occurs in the respiratory tract).
Particles which travel the length of the tract will be plated and studied for evidence of
colony forming units. This final step helps us to analyze the real world feasibility of the
technique and estimate how well the aerosol fingerprint will actually deliver active
vaccine to the human patient.
4. Data Logging and Analysis
We will acquire data logging hardware and software to record the variable
changes. The Dataq Instruments DI-710 Data Logger will suit our needs because of its
large number of channels (16) and flexible computer interface. The inputs and outputs
can be controlled with any common programming language. Although various data
logging software packages are available, writing our own will give us the flexibility we
need to include a large number of inputs and outputs, capture and record the data in
matrices we define, and formulate the optimization algorithm all within the same
framework.
5. Future Work
5.1 Integration with Development of Aerovax Device
The results of this experiment will be directly incorporated into the further
development of the Aerovax device. The current prototype will be modified to enable it
to produce effective aerosols of measles vaccine according to the aerosol fingerprint
identified. The device will be insulated against parameter changes that were identified
as detrimental to the vaccine aerosolization and incorporate features allowing the easy
control of parameters that need to be manipulated in order to increase the vaccine's
bioavailability post-nebulization. This might include thermal insulation, limited
adjustments to the vaccine formulation, better pressure regulation, and/or nebulizer
redesign to incorporate the optimal geometric parameters as identified by the
experiment.
5.2 Expansion to Other Vaccines
Although this initial experimentation and device deployment is targeted to the
measles vaccine, vaccination against other deadly diseases is also possible. Indeed, the
scale-up of this technology to vaccinate against other diseases is a long-term goal of the
project. Most of the aerosolized vaccine research has focused on measles given its high
prevalence. Very little research has been done into the possible aerosolization of other
vaccines.
The World Health Organization tracks "vaccine-preventable deaths" due to
numerous diseases, most notably Hemophilus influenza, pertussis, tetanus (neonatal
and nonneonatal), polio, diphtheria, and yellow fever. This proposed experimental
setup could be quite easily modified for use in identifying the optimal aerosol
fingerprint for each of these vaccines as well. Most sensors and actuators could remain
the same, although special consideration should be given to the issue of vaccine
reconstitution based on the specific biochemistry of the target vaccine. Also, although
the relevant post-aerosolization parameters remain relevant, their target values might
shift. The desired particle size distribution and drug delivery rate might be different
than those of measles vaccine based on biochemical and pharmaceutical properties.
6. Conclusion
The high prevalence of measles and the obstacles to vaccination that plague
much of the world pose serious challenges in the global health field. The development
of a new vaccination strategy is necessary. Measles vaccine administration via
inhalation has been demonstrated to be efficacious and safe, but little is known about
the best way to produce the vaccine aerosol.
The identification of an aerosol fingerprint would elucidate the parameters
necessary to optimize the nebulization process, which would in turn aid in the
development of a portable, safe, low-cost device able to operate in extreme field
conditions. The complex process of finding the optimization point can be automated
with the use of sensors, computer controlled actuators, and feedback loops. Special
consideration must be given to factors which might affect the bioavailability of the
vaccine, a concern not usually present in nebulizer experiments. The process can be
applied to the problem of identifying aerosol fingerprints for other important vaccines
with little modification.
Ultimately, the automation of the process provides a step forward in
understanding nebulizer technology as well as developing appropriate technology
solutions for health problems in resource-limited settings.
Appendix A: Summary Table of Variables
Variable Range of values Actuator Sensor Important
to be tested considerations
Relative 0-100% QuietCare Cool Honeywell HIH- Not controllable
Humidity Moisture 4000 Series in the field, not to
Humidifier be included in
(HCM650) optimization
algorithm
Nebulizer To be Amana Dryer Flexible Time dependency
Temperature determined Element Restring Hermetic Sealed must be
Kit PFA RTD Sensor addressed
Probe
Buffer Solution Tris-buffered Manually Manually May affect
saline; prepared recorded bioavailability
phosphate
buffered-saline
Solute To be Manually Manually Time dependent;
Concentration determined prepared recorded precipitation may
occur
Solution pH To be Manually Lazar Ultra-M May affect
determined prepared buffer micro pH bioavailability in
solution, electrode addition to PSD
dispensed
automatically
Surface full to minimum Automated Valued recorded Only to be
Tension values for each addition of from automated included in
solution surfactant dropper optimization
process after
bioavailability
has been verified
Air Pressure 30-70 psi Precision Medical Pressure None
EZ Neb PM7 regulator
Jet nozzle Available Multiple nebulizer Manually None
diameter dimensions; or models; or recorded; or
2-6 mm adjustable sensor to be
nebulizer built into
adjustable
design
Variable Range of values Actuator Sensor Important
to be tested considerations
Baffle surface Available Use of multiple Manually None
area dimensions; or nebulizer models; recorded; or
1-10 mm 2  or adjustable sensor to be
nebulizer built into
adjustable
design
Distance Available Use of multiple Manually None
between jet dimensions; or nebulizer models; recorded; or
nozzle and 1-5 mm or adjustable sensor to be
baffle nebulizer built into
adjustable
design
Particle Size n/a n/a Malvern None
Distribution Spraytec Laser
Diffraction
sensor
Drug Delivery n/a n/a Gravimetric Will determine
Rate measurement vaccination time
Aerosol n/a n/a Post-plating None
Endurance and CFU counts
Bioavailability
Figure 4. Summary of measured variable measurement, control, and special
considerations.
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